Alberto Bardelli
机构: University of Torino and IFOM ETS
每年引用次数
引用次数
引用: 76,178
H-指数: 113
I10-指数 : 275
出版物: 567
EVALUATION OF DRUG RESPONSES IN NON-TRANSFORMED CELLS CARRYING CANCER ALLELES
Giovanni Battista Appendino , M Geuna , Enzo Medico , Roberto Fantozzi
34° Congresso Nazionale della Società Italiana di Farmacologia 14 -14
2009
Knock in of cancer mutations in human cells predicts pharmacologicalresponse to targeted therapies
Federica Di Nicolantonio , Margherita Gallicchio , Alberto Bardelli , Davide Zecchin
III CONVEGNO MONOTEMATICO SIF - FARMACOGENOMICA E CANCRO: DAL LABORATORIO ALLA CLINICA 14 -14
2011
Unveiling of BRAF V600E Mutant Cells Sensitivity to Proteasome Inhibitors Using an Isogenic Cell Based Screening
Federica Di Nicolantonio , Margherita Gallicchio , Alberto Bardelli , Davide Zecchin
36° CONGRESSO NAZIONALE DELLA SOCIETÀ ITALIANA DI FARMACOLOGIA 115 -115
2013
CD4 T cell dependent rejection of beta 2 microglobulin null mismatch repair deficient tumors.
Giovanni Germano , Steve Lu , Giuseppe Rospo , Simona Lamba
Cancer Discovery
1
2021
Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy.
Gabriele Picco , Salvatore Siena , Ruby Banerjee , Daniele Oddo
Cancer Discovery
35
2021
EGFR Amplification in Metastatic Colorectal Cancer.
Benedetta Mussolin , Massimo Milione , Gouri Nanjangud , Giovanni Randon
Journal of the National Cancer Institute
2021
Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ.
Michelangelo Cordenonsi , Silvio Bicciato , Andrea Cassingena , Claudio Tripodo
Nature Communications 12 ( 1) 2340 -2340
2021
Precision oncology in metastatic colorectal cancer - from biology to medicine.
Pietro Paolo Vitiello , Pietro Paolo Vitiello , Federica Di Nicolantonio , Livio Trusolino
Nature Reviews Clinical Oncology 1 -20
77
2021
T cells expressing receptor recombination/revision machinery are detected in the tumor microenvironment and expanded in genomically over-unstable models.
Claudia Chiodoni , Claudio Tripodo , Daniele Lecis , Antonino Fiannaca
Cancer immunology research
2021
Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment.
Alberto Bardelli , Mariangela Russo , Alberto Sogari
Cancer Discovery
2021
Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression.
Stefano Biffo , Alessio Amatu , Sergio Abrignani , Jens Geginat
Nature Immunology 22 ( 6) 735 -745
2021
Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers.
Alberto Bardelli , Andrea Sartore-Bianchi , Salvatore Siena , Gianluca Mauri
Cancers 13 ( 11) 2638
22
2021
Clinical and molecular landscape of metastatic colorectal cancer (mCRC) harboring ALK, ROS1, or NTRK 1, 2, 3 (NTRKs) rearrangements.
Filippo Pietrantonio , Federica Di Nicolantonio , Alexa Betzig Schrock , Jeeyun Lee
Journal of Clinical Oncology 35 589 -589
2017
Mutation enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced colorectal and other cancers.
Filip Janku , Afsaneh Barzi , Andrea Sartore-Bianchi , Takeo Fujii
Journal of Clinical Oncology 35 602 -602
2017
Abstract IA18: Cancer evolution as a therapeutic target
Alberto Bardelli
Clinical Cancer Research 24
2018
Abstract B11: Whole-exome sequencing analysis of urine transrenal tumor DNA in metastatic colorectal cancer patients
Giovanni Crisafulli , Benedetta Mussolin , Andrea Cassingena , Monica Montone
Clinical Cancer Research 26
2020
Abstract IA13: Tracking and targeting colorectal cancer evolution
Alberto Bardelli
Clinical Cancer Research 26
2020
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Alberto Bardelli , Salvatore Siena
Journal of Clinical Oncology 28 ( 7) 1254 -1261
565
2010
Abstract C68: Endogenous expression of an oncogenic PI3K mutation leads to epithelial‐mesenchymal transition (EMT) and invasiveness
Jeffrey J. Wallin , Jane Guan , Pete Haverty , Zora Modrusan
Molecular Cancer Therapeutics 8
2009
Abstract A70: Isogenic K-Ras mutant cancer cells: A novel platform for drug profiling.
John Goodall , Jessica Hunt , Zhiqiang Chen , Federica Di Nicolantonio
Molecular Cancer Therapeutics 10
2011